Shanghai ZhenGe Biotech raises USD100M Series C Funding

Shanghai ZhenGe Biotech is a Shanghai-based company that provides a macromolecular biologic drug CDMO service. It raised USD100M Series C funding.

download 15

Goldman Sachs Asset Management led the round. Sofina was a participant, as well as Novo Holdings A/S and Qiming Venture Capital. Qiming Capital, IDG Capital. Junxin Capital. Cowin Capital were also involved.

The company has raised US$225m so far. It plans to use the funds for its Good Manufacturing Practice (“GMP”) manufacturing capabilities to better serve domestic and international customers.

Shanghai ZhenGe Biotech, headed by Mr. Jianxin, is the Chairman and CEO. It offers Contract Development and Manufacturing Organization services and provides end-to-end solutions for customers to discover, develop and manufacture biologics, from concept to commercialization. It offers services such as macromolecule development analysis, cell line and process development and optimization. Pilot production, commercial CMO services, process validation research, process characterization, and drug analysis. Cell culture medium formulation development. Commercial production.

The company has been serving more than 100 customers in biopharmaceutical and biotech industries and has completed over 150 projects. These projects range from cell line development to Investigational New Drugs (IND) applications to large clinical phase production contracts. ZhenGe Biotech’s expertise has grown over the years to include monoclonal and bispecific antibody, Antibody Drug Conjugates, fusion proteins, and vaccines.

Customers can benefit from the company’s cell culture platform, metabolite and recombinant platform as well as custom medium development and production platform. ZhenGe Biotech also offers advanced analytical services such as Analytical Ultra-centrifugation, (AUC), to assist customers in overseas drug approval applications.

ZhenGe Biotech also has R&D centers in Shanghai and Maryland, USA. A 10,000m2 GMP pilot production centre in Lingang Special Area, China (Shanghai), Pilot Free Trade Zone, (FTZ), is a GMP medium production plant with an annual output 200 tons of dry powder. It also has a commercial manufacturing base that houses three bioreactors of 2,000L and three of 5,000L.

Get latest news from African Startup ecosystem

Latest stories

You might also like...